To evaluate choroidal morphological changes 3 and 6 months after intravitreal injection of Ranibizumab for exudative age related macular degeneration.METHODS:
Retrospective, nonrandomized study, including patients with exudative AMD treated with Ranibizumab intravitreal injection and followed during 6 months. Non treated eye of AMD patients will be consider as control. All patients underwent a complete ophthalmological examination. At baseline, 3 months and 6 months, foveal and non-subfoveal areas were evaluated with Spectralis optical coherence tomography on both eye: under the fovea and at 500 and 1500 μm nasally and temporaly.RESULTS and CONCLUSION:
All studied eyes had exudative AMD at baseline treated with at least 3 Ranibizumab (Three Ranibizumab followed by injections if necessary were done for each patients). The results will be presented during the meeting.